TN2015000140A1 - Modulation of androgen receptor expression - Google Patents

Modulation of androgen receptor expression

Info

Publication number: TN2015000140A1
Authority: TN; Tunisia
Prior art keywords: androgen receptor; inhibiting; cancer; modulation; cell
Prior art date: 2012-10-11

Application number

TNP2015000140A

Other languages

English (en)

Inventor

Robert A Macleod

Youngsoo Kim

Tianyuan Zhou

Susan M Freier

Punit P Seth

Eric Swayze

Brett P Monia

Original Assignee

Isis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-10-11

Filing date

2015-04-10

Publication date

2016-10-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50475891&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2015000140(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-04-10 Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc

2016-10-03 Publication of TN2015000140A1 publication Critical patent/TN2015000140A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)

TNP2015000140A 2012-10-11 2015-04-10 Modulation of androgen receptor expression TN2015000140A1 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201261712780P	2012-10-11	2012-10-11
US201261712756P	2012-10-11	2012-10-11
US201261723701P	2012-11-07	2012-11-07
US201361777895P	2013-03-12	2013-03-12
US201361777813P	2013-03-12	2013-03-12
US201361777851P	2013-03-12	2013-03-12
PCT/US2013/064479 WO2014059238A2 (fr)	2012-10-11	2013-10-11	Modulation de l'expression de récepteur d'androgène

Publications (1)

Publication Number	Publication Date
TN2015000140A1 true TN2015000140A1 (en)	2016-10-03

Family

ID=50475891

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2015000140A TN2015000140A1 (en)	2012-10-11	2015-04-10	Modulation of androgen receptor expression

Country Status (31)

Country	Link
US (3)	US9175291B2 (fr)
EP (1)	EP2906226B1 (fr)
JP (2)	JP6306598B2 (fr)
KR (1)	KR102124228B1 (fr)
CN (2)	CN104703610B (fr)
AP (1)	AP2015008368A0 (fr)
AR (1)	AR092982A1 (fr)
AU (2)	AU2013329070A1 (fr)
BR (1)	BR112015007878A2 (fr)
CA (1)	CA2887867C (fr)
CL (1)	CL2015000901A1 (fr)
CO (1)	CO7400882A2 (fr)
DK (1)	DK2906226T3 (fr)
DO (1)	DOP2015000083A (fr)
EC (1)	ECSP15012462A (fr)
ES (1)	ES2706387T3 (fr)
IL (2)	IL237855A0 (fr)
MX (1)	MX369207B (fr)
NI (1)	NI201500051A (fr)
NZ (1)	NZ706151A (fr)
PE (1)	PE20150722A1 (fr)
PH (1)	PH12015500788A1 (fr)
PL (1)	PL2906226T3 (fr)
PT (1)	PT2906226T (fr)
RU (1)	RU2670486C9 (fr)
SG (1)	SG11201502505UA (fr)
TN (1)	TN2015000140A1 (fr)
TW (1)	TW201420594A (fr)
UY (1)	UY35078A (fr)
WO (1)	WO2014059238A2 (fr)
ZA (1)	ZA201503203B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112014002200A2 (pt)	2011-07-29	2017-03-07	Medivation Prostate Therapeutics Inc	tratamento de câncer de mama
TWI596494B (zh)	2012-03-05	2017-08-21	Ｏｐｋｏ診斷法有限責任公司	預測前列腺癌風險及前列腺腺體體積之方法及裝置
US9175291B2 (en)	2012-10-11	2015-11-03	Isis Pharmaceuticals Inc.	Modulation of androgen receptor expression
US12326453B2 (en)	2014-03-28	2025-06-10	Opko Diagnostics, Llc	Compositions and methods for active surveillance of prostate cancer
KR102505543B1 (ko)	2014-03-28	2023-03-02	옵코 다이어그노스틱스, 엘엘씨	전립선암 진단에 관한 조성물 및 방법
EP3604556A1 (fr)	2014-12-12	2020-02-05	Medivation Prostate Therapeutics LLC	Procédé de prédiction de la réponse aux agents thérapeutiques du cancer du sein et procédé de traitement du cancer du sein
AU2016222546B2 (en)	2015-02-26	2020-01-23	Ionis Pharmaceuticals, Inc.	Allele specific modulators of P23H rhodopsin
UA124522C2 (uk)	2015-03-27	2021-10-05	Опко Дайегностікс, Елелсі	Спосіб кількісної оцінки рівнів простатичного антигену
EP3280448B1 (fr)	2015-04-10	2020-12-30	Capsugel Belgium NV	Formulations lipidiques d'acétate d'abiratérone
CN105492632B (zh) *	2015-07-01	2021-08-06	深圳市第二人民医院	一种检测与特发性无精子症相关的遗传标记的引物对
WO2017053999A1 (fr) *	2015-09-25	2017-03-30	Ionis Pharmaceuticals, Inc.	Composés conjugués antisens et leur utilisation
WO2017066697A1 (fr) *	2015-10-14	2017-04-20	Dou Qingping	Traitements et diagnostics de cancers
CN105541991B (zh) *	2015-12-16	2019-05-31	中国医科大学	Bap18在促进前列腺癌方面的应用
US10604759B2 (en) *	2016-01-15	2020-03-31	City Of Hope	Targeting glioblastoma stem cells through the TLX-TET3 axis
EP3417064A4 (fr) *	2016-02-18	2019-10-23	Ionis Pharmaceuticals, Inc.	Modulateurs d'arn activateur de klk3
WO2017207702A1 (fr) *	2016-06-02	2017-12-07	Sint-Augustinus	Variants d'épissage du récepteur des androgènes et thérapie de déprivation androgénique
JP2019535839A (ja)	2016-11-29	2019-12-12	ピュアテックヘルスエルエルシー	治療剤の送達のためのエクソソーム
US10933134B2 (en) *	2017-03-16	2021-03-02	Memorial Sloan Kettering Cancer Center	Combination therapies for treatment of cancer
CA3090901A1 (fr)	2018-02-12	2019-08-15	Ionis Pharmaceuticals, Inc.	Composes modifies et leurs utilisations
US11866689B2 (en)	2018-03-26	2024-01-09	Duke University	Splice-switching oligonucleotides and methods of use
CN109321569B (zh) *	2018-10-29	2022-04-12	迈杰转化医学研究(苏州)有限公司	一种引物探针组合物及其应用
TW202028222A (zh) *	2018-11-14	2020-08-01	美商Ionis製藥公司	Foxp3表現之調節劑
WO2020102560A1 (fr) *	2018-11-14	2020-05-22	Board Of Regents, The University Of Texas System	Méthodes pour le traitement de tumeurs à petites cellules rondes
KR102473989B1 (ko)	2018-11-28	2022-12-07	(주)바이오니아	안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물
WO2020148400A1 (fr) *	2019-01-16	2020-07-23	Stichting Katholieke Universiteit	Oligonucléotides antisens destinés à être utilisés dans le traitement d'un crpc
CN109880931A (zh) *	2019-04-11	2019-06-14	江苏省农业科学院	一种丝瓜抗黄瓜花叶病毒cmv主效qtl的slaf-snp分子标记方法及应用
WO2021021885A1 (fr) *	2019-07-29	2021-02-04	The Medical College Of Wisconsin, Inc.	Méthodes de traitement du cancer de la prostate à un stade avancé
EP3791930A1 (fr) *	2019-09-13	2021-03-17	Secarna Pharmaceuticals GmbH & Co. KG	Inhibiteur de l'expression de la méthadhérine
JP2023501352A (ja) *	2019-11-08	2023-01-18	アイオーニスファーマシューティカルズ，インコーポレーテッド	Ｓｐｄｅｆ発現を低減するための化合物及び方法
CN116370491A (zh) *	2021-09-22	2023-07-04	北京瑞博开拓医药科技有限公司	反义寡核苷酸剂在治疗冠状病毒相关疾病中的应用
CN116270710B (zh) *	2023-02-16	2025-01-28	南方医科大学珠江医院	circRBM33作为靶点在前列腺癌诊断和治疗中的应用
WO2024220955A2 (fr) *	2023-04-21	2024-10-24	Memorial Sloan Kettering Cancer Center	Combinaison d'induction de ferroptose avec des agents ciblés pour une thérapie anticancéreuse
CN119979543B (zh) *	2025-04-14	2025-07-22	羿美诚健(上海)生物医药有限公司	靶向雄激素受体的小核酸及其药物组合物和用途

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2699808A (en)	1944-10-06	1955-01-18	Mark W Lowe	Apparatus for peeling tomatoes
US2699508A (en)	1951-12-21	1955-01-11	Selectronics Inc	Method of mounting and construction of mounting for low frequency piezoelectric crystals
US5118800A (en)	1983-12-20	1992-06-02	California Institute Of Technology	Oligonucleotides possessing a primary amino group in the terminal nucleotide
FR2567892B1 (fr)	1984-07-19	1989-02-17	Centre Nat Rech Scient	Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5506337A (en)	1985-03-15	1996-04-09	Antivirals Inc.	Morpholino-subunit combinatorial library and method
US5185444A (en)	1985-03-15	1993-02-09	Anti-Gene Deveopment Group	Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en)	1989-12-20	1992-11-24	Anti-Gene Development Group	Sequence-specific binding polymers for duplex nucleic acids
US5034506A (en)	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
US5591722A (en)	1989-09-15	1997-01-07	Southern Research Institute	2'-deoxy-4'-thioribonucleosides and their antiviral activity
EP0497875B1 (fr)	1989-10-24	2000-03-22	Isis Pharmaceuticals, Inc.	Oligonucleotides modifies en position 2'
US5670633A (en)	1990-01-11	1997-09-23	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides that detect and modulate gene expression
US5646265A (en)	1990-01-11	1997-07-08	Isis Pharmceuticals, Inc.	Process for the preparation of 2'-O-alkyl purine phosphoramidites
GB9009980D0 (en)	1990-05-03	1990-06-27	Amersham Int Plc	Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
ATE167523T1 (de)	1990-05-11	1998-07-15	Microprobe Corp	Teststreifen zum eintauchen für nukleinsäure- hybridisierungsassays und verfahren zur kovalenten immobilisierung von oligonucleotiden
US6582908B2 (en)	1990-12-06	2003-06-24	Affymetrix, Inc.	Oligonucleotides
US5877160A (en)	1991-05-31	1999-03-02	Genta Incorporated	Compositions and methods of treatment of androgen-associated baldness using antisense oligomers
US7517644B1 (en)	1991-08-23	2009-04-14	Larry J. Smith	Method and compositions for cellular reprogramming
DE59208572D1 (de)	1991-10-17	1997-07-10	Ciba Geigy Ag	Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5359044A (en)	1991-12-13	1994-10-25	Isis Pharmaceuticals	Cyclobutyl oligonucleotide surrogates
FR2687679B1 (fr)	1992-02-05	1994-10-28	Centre Nat Rech Scient	Oligothionucleotides.
EP0577558A2 (fr)	1992-07-01	1994-01-05	Ciba-Geigy Ag	Nucléosides carbocycliques contenant des noyaux bicycliques, oligonucléotides en dérivant, procédé pour leur préparation, leur application et des intermédiaires
JPH08504559A (ja)	1992-12-14	1996-05-14	ハネウエル・インコーポレーテッド	個別に制御される冗長巻線を有するモータシステム
WO1994018835A1 (fr)	1993-02-19	1994-09-01	Genta Incorporated	Traitement de la calvitie associee aux androgenes au moyen d'oligomeres antisens
ATE155467T1 (de)	1993-03-30	1997-08-15	Sanofi Sa	Acyclische nucleosid analoge und sie enthaltende oligonucleotidsequenzen
US5801154A (en)	1993-10-18	1998-09-01	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5556956A (en)	1993-11-04	1996-09-17	Board Of Regents, The University Of Texas System	Methods and compositions relating to the androgen receptor gene and uses thereof
US5446137B1 (en)	1993-12-09	1998-10-06	Behringwerke Ag	Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en)	1994-01-11	1996-05-21	Isis Pharmaceuticals, Inc.	Pyrrolidine-containing monomers and oligomers
US5627053A (en)	1994-03-29	1997-05-06	Ribozyme Pharmaceuticals, Inc.	2'deoxy-2'-alkylnucleotide containing nucleic acid
US5597909A (en)	1994-08-25	1997-01-28	Chiron Corporation	Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
EP0851919A1 (fr)	1995-09-20	1998-07-08	University of Massachusetts Worcester	Chimiotherapie par oligonucleotides antisens de l'hypertrophie ou du cancer de la prostate
US6300060B1 (en)	1995-11-09	2001-10-09	Dana-Farber Cancer Institute, Inc.	Method for predicting the risk of prostate cancer morbidity and mortality
US5656408A (en)	1996-04-29	1997-08-12	Xerox Corporation	Coated carrier particles
US6489163B1 (en)	1996-05-08	2002-12-03	Board Of Regents, The University Of Texas System	Ribozyme mediated inactivation of the androgen receptor
JP3756313B2 (ja)	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6770748B2 (en)	1997-03-07	2004-08-03	Takeshi Imanishi	Bicyclonucleoside and oligonucleotide analogue
US5994076A (en)	1997-05-21	1999-11-30	Clontech Laboratories, Inc.	Methods of assaying differential expression
US6794499B2 (en)	1997-09-12	2004-09-21	Exiqon A/S	Oligonucleotide analogues
ATE293123T1 (de)	1997-09-12	2005-04-15	Exiqon As	Bi- und tri-zyklische - nukleosid, nukleotid und oligonukleotid-analoga
US20030228597A1 (en)	1998-04-13	2003-12-11	Cowsert Lex M.	Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US6043352A (en)	1998-08-07	2000-03-28	Isis Pharmaceuticals, Inc.	2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
EP1114179A2 (fr)	1998-09-15	2001-07-11	Signalgene Inc.	Marqueur au niveau du gene recepteur des hormones androgenes pour la determination de la sensibilite au cancer du sein
IL145778A0 (en)	1999-04-21	2002-07-25	American Home Prod	Methods and compositions for inhibiting the function of polynucleotide sequences
CA2372085C (fr)	1999-05-04	2009-10-27	Exiqon A/S	Analogues de l-ribo-lna
US6525191B1 (en)	1999-05-11	2003-02-25	Kanda S. Ramasamy	Conformationally constrained L-nucleosides
DE60027203T2 (de)	1999-12-30	2007-01-04	K.U. Leuven Research & Development	Cyclohexennukleinsäuren
US6255110B1 (en)	2000-01-21	2001-07-03	Isis Pharmaceuticals, Inc.	Antisense modulation of ARA70 expression
WO2001073116A2 (fr)	2000-03-28	2001-10-04	Signalgene Inc.	Methode permettant de determiner la probabilite d'etre atteint d'osteoporose et/ou une faible densite osseuse, et reactifs destines a cette methode
US20040241651A1 (en)	2000-04-07	2004-12-02	Alexander Olek	Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations
KR20020097241A (ko)	2000-05-04	2002-12-31	에이브이아이 바이오파마 인코포레이티드	스플라이스-영역 안티센스 조성물 및 방법
MXPA02012573A (es)	2000-06-28	2003-05-14	Squibb Bristol Myers Co	Lineas de celulas y ensayos en base a celulas para la identificacion de moduladores de receptores de androgeno.
AU8821301A (en)	2000-06-28	2002-01-08	Bristol Myers Squibb Co	Selective androgen receptor modulators and methods for their identification, design and use
RU2003102390A (ru) *	2000-06-28	2004-05-27	Бристол-Маерс Сквибб Компани (Us)	Селективные модуляторы рецептора андрогена и способы их идентификации, изготовления и применения
AU2001278068A1 (en)	2000-07-27	2002-02-13	University Of Rochester	Methods and compositions for predicting prostate cancer
US20020165381A1 (en)	2000-11-30	2002-11-07	Isabelle Ahrens-Fath	Human androgen receptor variants
JP2002247986A (ja)	2001-02-23	2002-09-03	Mitsui Chemicals Inc	性ホルモン受容体作用評価に有用な細胞
WO2002085308A2 (fr)	2001-04-24	2002-10-31	Epigenesis Pharmaceuticals, Inc.	Compositions, formulations et trousses contenant des oligonucleotides anti-sens et des steroides anti-inflammatoires et/ou un ubiquinone pour le traitement de maladies respiratoires ou pulmonaires
US20050159376A1 (en)	2002-02-20	2005-07-21	Slrna Therapeutics, Inc.	RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
CA2452458A1 (fr)	2001-07-03	2003-01-16	Isis Pharmaceuticals, Inc.	Oligonucleotides chimeres resistants a la nuclease
US6680342B2 (en)	2001-09-20	2004-01-20	Mayo Foundation For Medical Education And Research	Methods and compositions for inhibiting the proliferation of prostate cancer cells
FR2832154B1 (fr)	2001-11-09	2007-03-16	Centre Nat Rech Scient	Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
US6861432B2 (en)	2001-11-23	2005-03-01	Schering Aktiengesellschaft	Piperazine derivatives that destabilize androgen receptors
JP2004008140A (ja)	2002-06-10	2004-01-15	Sumitomo Chem Co Ltd	変異型アンドロゲンレセプターおよびその活性評価用細胞
WO2004011624A2 (fr)	2002-07-31	2004-02-05	Nucleonics, Inc.	Structures et constructions d'arn a double brin, et leurs procedes de production et d'utilisation
EP1572964A4 (fr)	2002-10-18	2007-08-08	Nucleonics Inc	Structures et constructions d'arn a double brin et procedes pour leur generation et leur utilisation
WO2004041277A1 (fr)	2002-11-01	2004-05-21	Merck & Co., Inc.	Derives de carbonylamino-benzimidazole utilises comme modulateurs du recepteur androgene
CA2504694C (fr)	2002-11-05	2013-10-01	Isis Pharmaceuticals, Inc.	Composes oligomeres renfermant un substitut de sucre polycyclique et compositions intervenant dans la modulation genique
US8604183B2 (en)	2002-11-05	2013-12-10	Isis Pharmaceuticals, Inc.	Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
EP2213738B1 (fr)	2002-11-14	2012-10-10	Dharmacon, Inc.	Molécules siRNA anti Bcl-2
US6673661B1 (en)	2002-12-20	2004-01-06	Taiwan Semiconductor Manufacturing Co., Ltd.	Self-aligned method for forming dual gate thin film transistor (TFT) device
CA2512337A1 (fr)	2003-01-03	2004-07-29	Gencia Corporation	Silencage genique post-transcriptionnel medie par arnsi de genes impliques dans l'alopecie
EP1587804A1 (fr)	2003-01-17	2005-10-26	Warner-Lambert Company LLC	Antagonistes du recepteur des androgenes
JP2004254601A (ja)	2003-02-26	2004-09-16	Sumitomo Chem Co Ltd	変異型アンドロゲンレセプターおよびその活性評価用細胞
JP2004254600A (ja)	2003-02-26	2004-09-16	Sumitomo Chem Co Ltd	変異型アンドロゲンレセプターおよびその活性評価用細胞
DE10322108B4 (de)	2003-05-09	2008-12-11	Bayer Schering Pharma Aktiengesellschaft	Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit
WO2004106356A1 (fr)	2003-05-27	2004-12-09	Syddansk Universitet	Derives de nucleotides fonctionnalises
JP4731324B2 (ja)	2003-08-28	2011-07-20	武今西	Ｎ−ｏ結合性架橋構造型新規人工核酸
WO2005027962A1 (fr)	2003-09-18	2005-03-31	Isis Pharmaceuticals, Inc.	4’-thionucleosides et composes d'oligomeres
US20050164970A1 (en)	2003-12-22	2005-07-28	University Of Kansas Medical Center	Method for treating prostate cancer using siRNA duplex for androgen receptor
US20050244851A1 (en)	2004-01-13	2005-11-03	Affymetrix, Inc.	Methods of analysis of alternative splicing in human
EP1716164A1 (fr)	2004-02-20	2006-11-02	Genesis Research and Development Corporation Limited	Diffusion ciblee de molecule d'interference arn pour le traitement de troubles facilites par ige
US7696241B2 (en)	2004-03-04	2010-04-13	Bristol-Myers Squibb Company	Bicyclic compounds as modulators of androgen receptor function and method
KR20070085113A (ko)	2004-05-11	2007-08-27	가부시키가이샤 알파젠	Rna간섭을 생기게 하는 폴리뉴클레오티드, 및 이를 이용한유전자발현억제 방법
AU2005247405A1 (en)	2004-05-17	2005-12-08	Acadia Pharmaceuticals Inc.	Androgen receptor modulators and method of treating disease using the same
DE102004025881A1 (de)	2004-05-19	2006-01-05	Beiersdorf Ag	Oligoribonukleotide zur Beeinflussung des Haarwachstums
CA2569419A1 (fr)	2004-06-03	2005-12-22	Isis Pharmaceuticals, Inc.	Compositions a double brin comprenant des brins differentiellement modifies utilises dans la modulation genetique
CA2576233C (fr)	2004-08-10	2016-03-15	Alnylam Pharmaceuticals, Inc.	Conjugue comprenant un antagomir et un ligand
US20080261905A1 (en)	2004-11-08	2008-10-23	K.U. Leuven Research And Development	Modified Nucleosides for Rna Interference
US20070248535A1 (en)	2005-02-07	2007-10-25	The Trustees Of Columbia University In The City Of New York	Methods to treat or prevent hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity
US20070154896A1 (en)	2005-02-11	2007-07-05	International Business Machines Corporation	System and method for identification of MicroRNA target sites and corresponding targeting MicroRNA sequences
US8912317B2 (en)	2005-02-11	2014-12-16	International Business Machines Corporation	Ribonucleic acid interference molecules of Arabidopsis thaliana
US8795987B2 (en)	2005-02-11	2014-08-05	International Business Machines Corporation	Ribonucleic acid interference molecules of Oryza sativa
US20070213293A1 (en)	2005-04-08	2007-09-13	Nastech Pharmaceutical Company Inc.	Rnai therapeutic for respiratory virus infection
US7709517B2 (en)	2005-05-13	2010-05-04	The Regents Of The University Of California	Diarylhydantoin compounds
US20070111227A1 (en)	2005-07-28	2007-05-17	Green Pamela J	Small regulatory RNAs and methods of use
US7700567B2 (en)	2005-09-29	2010-04-20	Supergen, Inc.	Oligonucleotide analogues incorporating 5-aza-cytosine therein
EP1984381B1 (fr)	2006-01-27	2010-09-29	Isis Pharmaceuticals, Inc.	Analogues d'acides nucleiques bicycliques modifies en position 6
JP4961549B2 (ja)	2006-02-16	2012-06-27	国立大学法人愛媛大学	アンドロゲン受容体遺伝子に特異的なｓｉＲＮＡ
US8178503B2 (en)	2006-03-03	2012-05-15	International Business Machines Corporation	Ribonucleic acid interference molecules and binding sites derived by analyzing intergenic and intronic regions of genomes
DK2656842T3 (en)	2006-03-27	2016-11-07	Univ California	Androgen receptor MODULATOR FOR THE TREATMENT OF PROSTATE CANCER AND androgen receptor-ASSOCIATED DISEASES
JP2007282598A (ja)	2006-04-19	2007-11-01	Japan Health Science Foundation	性分化異常症診断マーカー
DK2066684T3 (da)	2006-05-11	2012-10-22	Isis Pharmaceuticals Inc	5´-Modificerede bicycliske nukleinsyreanaloge
JP4798093B2 (ja)	2006-08-04	2011-10-19	日産自動車株式会社	流体改質装置及びこれを用いた流体改質方法
AR055648A1 (es)	2006-09-21	2007-08-29	Gen Med Sa	Un oligonucleotido de rna de doble cadena una composicion farmaceutica o cosmetica que lo comprende y uso del mismo enla preparacion de un medicamento para el tratamiento de enfermedades relacionadas con el metabolismo de androgenos
WO2008070862A2 (fr)	2006-12-07	2008-06-12	Biocept, Inc.	Dépistage génétique prénatal non invasif
WO2008076918A2 (fr)	2006-12-15	2008-06-26	University Of Maryland, Baltimore	Agents anti-cancer et composé inhibant l'activité androgène
EP2125852B1 (fr)	2007-02-15	2016-04-06	Ionis Pharmaceuticals, Inc.	Nucléosides modifiés 5'-substitués-2'-f et composés oligomères préparés à partir de ceux-ci
WO2008119015A2 (fr)	2007-03-27	2008-10-02	Sloan-Kettering Institute For Cancer Research	Synthèse de dérivés de la thiohydantoïne
AU2008260277C1 (en)	2007-05-30	2014-04-17	Isis Pharmaceuticals, Inc.	N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
DK2173760T4 (en)	2007-06-08	2016-02-08	Isis Pharmaceuticals Inc	Carbocyclic bicyclic nukleinsyreanaloge
CN101796062B (zh)	2007-07-05	2014-07-30	Isis制药公司	6-双取代双环核酸类似物
US8486904B2 (en) *	2007-10-01	2013-07-16	Isis Pharmaceuticals, Inc.	Antisense modulation of fibroblast growth factor receptor 4 expression
WO2009067647A1 (fr)	2007-11-21	2009-05-28	Isis Pharmaceuticals, Inc.	Analogues d'acide nucléique alpha-l-bicyclique carbocyclique
US8450290B2 (en)	2007-11-26	2013-05-28	Enzon Pharmaceuticals, Inc.	Methods for treating androgen receptor dependent disorders including cancers
JP5872162B2 (ja) *	2007-11-26	2016-03-01	エンゾンファーマシューティカルズ，インコーポレーテッド	アンドロゲン受容体を標的化するｌｎａアンタゴニスト
BRPI0821676A2 (pt)	2007-12-21	2015-06-16	Astrazeneca Ab	Composto, composição farmacêutica, e, processo para a preparação dos compostos.
EP2265627A2 (fr)	2008-02-07	2010-12-29	Isis Pharmaceuticals, Inc.	Analogues d acides nucléiques de cyclohexitol bicycliques
CA2715380A1 (fr)	2008-02-12	2009-08-20	The Brigham And Women's Hospital, Inc.	Dosage fish pour detecter la fusion entre eml4 et alk dans le cancer du poumon
FR2929292A1 (fr)	2008-03-28	2009-10-02	Exonhit Therapeutics S A Sa	Procede et methodes de diagnostic de la maladie d'alzheimer
US20090282496A1 (en)	2008-04-04	2009-11-12	University Of Rochester Medical Center	Androgen Receptor Related Methods for Treating Bladder Cancer
US9146238B2 (en)	2008-04-16	2015-09-29	The Johns Hopkins University	Compositions and methods for treating or preventing prostate cancer and for detecting androgen receptor variants
MX2011002143A (es)	2008-08-25	2011-07-20	Excaliard Pharmaceuticals Inc	Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos.
US8133724B2 (en)	2008-09-17	2012-03-13	University Of Maryland, Baltimore	Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
EP2361256B1 (fr)	2008-09-24	2013-04-10	Isis Pharmaceuticals, Inc.	Analogues d'acide nucléique cyclohexényle
WO2010036698A1 (fr)	2008-09-24	2010-04-01	Isis Pharmaceuticals, Inc.	Nucléosides alpha-l-bicycliques substitués
WO2010062914A1 (fr)	2008-11-26	2010-06-03	The Johns Hopkins University	Procédés d'identification d'un risque de cancer
US8202690B2 (en)	2008-11-28	2012-06-19	Hisamitsu Pharmaceutical Co., Inc.	Cancer marker and therapeutic agent for cancer
US20140154783A1 (en)	2009-07-06	2014-06-05	Alnylam Pharmaceuticals, Inc.	Bioprocessing
CA2767231A1 (fr)	2009-07-06	2011-01-13	Alnylam Pharmaceuticals, Inc.	Biotraitement a base de cellules
AU2011218173C1 (en)	2010-02-16	2015-04-16	Aragon Pharmaceuticals, Inc.	Androgen receptor modulators and uses thereof
EP2545186A1 (fr)	2010-03-08	2013-01-16	Regents Of The University Of Minnesota	Isoformes du récepteur aux androgènes et procédés associés
US9068185B2 (en)	2010-03-12	2015-06-30	Sarepta Therapeutics, Inc.	Antisense modulation of nuclear hormone receptors
US8993738B2 (en)	2010-04-28	2015-03-31	Isis Pharmaceuticals, Inc.	Modified nucleosides, analogs thereof and oligomeric compounds prepared therefrom
KR102095478B1 (ko)	2010-05-28	2020-04-01	사렙타 쎄러퓨틱스, 인코퍼레이티드	변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
WO2012005898A2 (fr)	2010-06-15	2012-01-12	Alnylam Pharmaceuticals, Inc.	Transcriptome de cellules d'ovaire de hamster chinois (cho), arnsi correspondants et utilisations de ceux-ci
EP2591104A4 (fr) *	2010-07-06	2014-09-03	Dicerna Pharmaceuticals Inc	Procédés et compositions pour l'inhibition spécifique du récepteur des androgènes par arn double brin
DK3031920T3 (da) *	2010-07-19	2019-10-14	Ionis Pharmaceuticals Inc	Modulation af dystrofi myotonica-protein kinase (dmpk) ekspression
WO2012018881A2 (fr)	2010-08-03	2012-02-09	Alnylam Pharmaceuticals, Inc.	Procédés et compositions pour la régulation d'arn
AU2011326034B2 (en)	2010-11-12	2016-02-04	Roche Innovation Center Copenhagen A/S	Compositions and methods for treating androgen receptor dependent disorders including cancers
CA2822462A1 (fr)	2010-12-20	2012-06-28	The General Hospital Corporation	Arn non codants associes a polycomb
US9173894B2 (en)	2011-02-02	2015-11-03	Excaliard Pharamaceuticals, Inc.	Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
EP3067421B1 (fr)	2011-02-08	2018-10-10	Ionis Pharmaceuticals, Inc.	Composés oligomères comprenant des nucléotides bicycliques et leurs utilisations
EP2683834B1 (fr)	2011-03-10	2017-12-06	Oslo Universitetssykehus HF	Méthodes et biomarqueurs de détection de cancers gastro-intestinaux
US10023861B2 (en)	2011-08-29	2018-07-17	Ionis Pharmaceuticals, Inc.	Oligomer-conjugate complexes and their use
US20140378533A1 (en)	2012-02-08	2014-12-25	Isis Pharmaceuticals, Inc.	Modulation of rna by repeat targeting
US9778706B2 (en)	2012-02-24	2017-10-03	Blackberry Limited	Peekable user interface on a portable electronic device
US9984408B1 (en)	2012-05-30	2018-05-29	Amazon Technologies, Inc.	Method, medium, and system for live video cooperative shopping
US9175291B2 (en) *	2012-10-11	2015-11-03	Isis Pharmaceuticals Inc.	Modulation of androgen receptor expression

2013
- 2013-10-10 US US14/050,574 patent/US9175291B2/en active Active
- 2013-10-10 AR ARP130103693A patent/AR092982A1/es unknown
- 2013-10-11 PL PL13845244T patent/PL2906226T3/pl unknown
- 2013-10-11 UY UY0001035078A patent/UY35078A/es not_active Application Discontinuation
- 2013-10-11 ES ES13845244T patent/ES2706387T3/es active Active
- 2013-10-11 AU AU2013329070A patent/AU2013329070A1/en not_active Abandoned
- 2013-10-11 TW TW102136853A patent/TW201420594A/zh unknown
- 2013-10-11 EP EP13845244.6A patent/EP2906226B1/fr active Active
- 2013-10-11 MX MX2015004641A patent/MX369207B/es active IP Right Grant
- 2013-10-11 BR BR112015007878A patent/BR112015007878A2/pt not_active IP Right Cessation
- 2013-10-11 KR KR1020157012332A patent/KR102124228B1/ko not_active Expired - Fee Related
- 2013-10-11 NZ NZ706151A patent/NZ706151A/en not_active IP Right Cessation
- 2013-10-11 JP JP2015536917A patent/JP6306598B2/ja active Active
- 2013-10-11 DK DK13845244.6T patent/DK2906226T3/en active
- 2013-10-11 AP AP2015008368A patent/AP2015008368A0/xx unknown
- 2013-10-11 PE PE2015000467A patent/PE20150722A1/es not_active Application Discontinuation
- 2013-10-11 CN CN201380052830.2A patent/CN104703610B/zh active Active
- 2013-10-11 CA CA2887867A patent/CA2887867C/fr active Active
- 2013-10-11 CN CN201810067329.8A patent/CN108300718B/zh active Active
- 2013-10-11 WO PCT/US2013/064479 patent/WO2014059238A2/fr not_active Ceased
- 2013-10-11 PT PT13845244T patent/PT2906226T/pt unknown
- 2013-10-11 RU RU2015111672A patent/RU2670486C9/ru active
- 2013-10-11 SG SG11201502505UA patent/SG11201502505UA/en unknown
2015
- 2015-03-19 IL IL237855A patent/IL237855A0/en unknown
- 2015-03-31 EC ECIEPI201512462A patent/ECSP15012462A/es unknown
- 2015-04-09 CO CO15078897A patent/CO7400882A2/es unknown
- 2015-04-09 NI NI201500051A patent/NI201500051A/es unknown
- 2015-04-09 CL CL2015000901A patent/CL2015000901A1/es unknown
- 2015-04-09 DO DO2015000083A patent/DOP2015000083A/es unknown
- 2015-04-10 TN TNP2015000140A patent/TN2015000140A1/fr unknown
- 2015-04-10 PH PH12015500788A patent/PH12015500788A1/en unknown
- 2015-05-08 ZA ZA2015/03203A patent/ZA201503203B/en unknown
- 2015-09-15 US US14/854,281 patent/US9567588B2/en not_active Ceased
2017
- 2017-02-03 AU AU2017200759A patent/AU2017200759B2/en not_active Ceased
2018
- 2018-03-07 JP JP2018040594A patent/JP6599497B2/ja not_active Expired - Fee Related
- 2018-10-08 IL IL262218A patent/IL262218B/en active IP Right Grant
2019
- 2019-02-13 US US16/275,198 patent/USRE48461E1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PE20150722A1 (es)	2015-06-03
AU2017200759A1 (en)	2017-03-02
CN104703610A (zh)	2015-06-10
HK1258404A1 (zh)	2019-11-08
IL262218A (en)	2018-11-29
CA2887867A1 (fr)	2014-04-17
WO2014059238A2 (fr)	2014-04-17
CN104703610B (zh)	2018-03-23
BR112015007878A2 (pt)	2017-11-28
RU2015111672A (ru)	2016-12-10
PH12015500788A1 (en)	2015-06-15
IL262218B (en)	2020-08-31
CA2887867C (fr)	2019-09-24
TW201420594A (zh)	2014-06-01
AR092982A1 (es)	2015-05-13
PL2906226T3 (pl)	2019-04-30
WO2014059238A3 (fr)	2014-06-19
US20140107180A1 (en)	2014-04-17
RU2670486C2 (ru)	2018-10-23
JP6306598B2 (ja)	2018-04-04
UY35078A (es)	2014-03-31
US20160068846A1 (en)	2016-03-10
AU2013329070A1 (en)	2015-04-16
USRE48461E1 (en)	2021-03-09
IL237855A0 (en)	2015-05-31
DK2906226T3 (en)	2019-02-18
MX369207B (es)	2019-10-31
DOP2015000083A (es)	2015-06-15
KR20150064210A (ko)	2015-06-10
JP2018126141A (ja)	2018-08-16
SG11201502505UA (en)	2015-04-29
CN108300718A (zh)	2018-07-20
US9567588B2 (en)	2017-02-14
AP2015008368A0 (en)	2015-04-30
PT2906226T (pt)	2019-02-25
RU2670486C9 (ru)	2019-04-01
NZ706151A (en)	2018-11-30
JP2016501513A (ja)	2016-01-21
NI201500051A (es)	2016-02-15
JP6599497B2 (ja)	2019-10-30
ES2706387T3 (es)	2019-03-28
EP2906226B1 (fr)	2018-11-21
US9175291B2 (en)	2015-11-03
MX2015004641A (es)	2015-07-14
WO2014059238A8 (fr)	2015-04-16
EP2906226A2 (fr)	2015-08-19
CL2015000901A1 (es)	2016-02-26
HK1213774A1 (en)	2016-07-15
EP2906226A4 (fr)	2016-06-08
CN108300718B (zh)	2022-02-22
ZA201503203B (en)	2016-09-28
ECSP15012462A (es)	2015-12-31
CO7400882A2 (es)	2015-09-30
KR102124228B1 (ko)	2020-06-17
AU2017200759B2 (en)	2018-07-19

Publication	Publication Date	Title
TN2015000140A1 (en)	2016-10-03	Modulation of androgen receptor expression
PH12012502194A1 (en)	2014-09-05	Indoles
PH12014500248B1 (en)	2018-08-31	Treatment of breast cancer
PH12014502445B1 (en)	2019-11-15	Targeted modification of malate dehydrogenase
MX2011007420A (es)	2011-12-14	Compuestos, composiciones y metodos para prevenir la metastasis de las celulas cancerigenas.
MX360404B (es)	2018-10-31	Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
EA201390756A1 (ru)	2014-11-28	Модулирующие nk-клетки терапии и способы для лечения гематологических злокачественных заболеваний
WO2010141738A3 (fr)	2011-03-17	Compositions et procédé pour inhiber la croissance d'une tumeur
PH12018502569A1 (en)	2020-12-07	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
WO2011083090A3 (fr)	2011-10-06	Méthodes de traitement du cancer du sein
MX2013007268A (es)	2013-12-06	Activadores de pkm2 bicíclicos.
NZ700612A (en)	2016-09-30	Methods and compositions for treating ewings sarcoma family of tumors
WO2013152120A3 (fr)	2013-12-19	Compositions et méthodes pour la promotion de la fonction de cellules souches intestinales
MX364002B (es)	2019-04-10	Compuestos y composiciones activadoras de enzima.
MX360774B (es)	2018-11-15	Antagonistas de progesterona.
WO2012170742A3 (fr)	2013-04-04	Traitement et prévention du cancer avec des antagonistes du hmgb1
MX2015013021A (es)	2016-07-14	5-bromo-indirrubinas.
WO2018193476A3 (fr)	2019-01-03	Composés anticancéreux
GB2528604A (en)	2016-01-27	Modulation of asymmetric proliferation
MX363077B (es)	2019-03-07	Inhibidores de metastasis.
GB201213866D0 (en)	2012-09-19	Cancer stem cell inhibition